km-819
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT03022799)
Timeline
Indications
Mechanism of action
- FAS-associated factor 1INHIBITOR
FAF1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- km-819
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05695378 | Phase 2 | Feb 27, 2023 | Fudan University, Kainos Medicine Inc., Parexel |
| NCT05670782 | Phase 2 | Jul 19, 2022 | FAScinate Therapeutics Inc., Parexel |
| NCT03022799 | Phase 1 | Oct 1, 2016 | Kainos Medicine Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kainos Medicine Inc. | For profit | 2 | 2 | 2 | 2016 |
| Parexel | For profit | 2 | 0 | 1 | 2022 |
| FAScinate Therapeutics Inc. | For profit | 1 | 1 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1